SCHEMBL4765453

SCHEMBL4765453

COc1[nH][c]nc1-c1cccc2ccccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.38
BCHE P06276 1/20 0.38
PGK1 P00558 1/20 0.37
ALOX15 P16050 1/20 0.37
GSK3B P49841 1/20 0.36
ADK P55263 1/20 0.36
ALOX5 P09917 1/20 0.36
NISCH Q9Y2I1 1/20 0.36
MAPT P10636 3/20 0.35
ALDH1A1 P00352 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
HPGD P15428 1/20 0.35
DHFR P00374 1/20 0.34
MAPK11 Q15759 1/20 0.34
MAPK14 Q16539 1/20 0.34
MTNR1A P48039 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4764109 0.84 ENPP1 (0.39) BCHEPGK1ALOX15GSK3BADK
SCHEMBL4722240 0.82 HTR1B (0.37) BCHEPGK1ALOX15MAPTALDH1A1
SCHEMBL5097262 0.81 TLR8 (0.39) BCHEALDH1A1CYP2C9PPARGPPARA
SCHEMBL4722365 0.73 KDM4E (0.38) PDGFRBALOX15GSK3BADKALOX5
SCHEMBL8564303 0.72 BCHE (0.38) BCHEALOX15GSK3BNISCHMAPT
SCHEMBL8566667 0.72 MAPT (0.45) PDGFRBPGK1GSK3BADKNISCH
SCHEMBL8560624 0.71 BCHE (0.51) BCHEGSK3BNISCHMAPTALDH1A1
SCHEMBL6489268 0.70 BCHE (0.40) BCHEALOX15GSK3BADKNISCH
SCHEMBL4720658 0.70 PGK1 (0.37) PDGFRBBCHEPGK1ALOX15ALOX5
SCHEMBL4767199 0.70 BCHE (0.38) PDGFRBBCHEPGK1ALOX15ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 PDGFRB 39/4885BCHE 3103/4885PGK1 1835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.